Hohenrainstrasse 24
Pratteln 4133
Switzerland
41 61 906 89 50
https://www.santhera.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Thomas Meier Ph.D. | Founder & Chairman | 100k | N/D | 1962 |
Mr. Dario Eklund | Chief Executive Officer | 1M | N/D | 1968 |
Mr. Andrew P. Smith CGMA, FCMA | Chief Financial Officer | N/D | N/D | 1962 |
Mr. Oliver Strub | General Counsel & Secretary | N/D | N/D | 1963 |
Mr. Günther Metz Ph.D. | Head Business Development | N/D | N/D | 1958 |
Mr. Shabir Hasham M.D. | Chief Medical Officer | N/D | N/D | N/D |
Mr. Marc Schrader | Chief Technology Officer | N/D | N/D | N/D |
Ms. Eva Kalias | Head of Investor Relations & Communications | N/D | N/D | N/D |
Mr. Neville Kodkani M.D. | Head of Global Marketing & Partner Management | N/D | N/D | N/D |
Ms. Sarah Holmes-Klotz | Head of People & Culture | N/D | N/D | N/D |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
L'ISS Governance QualityScore di Santhera Pharmaceuticals Holding AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.